Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 10/20 | 0.56 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.54 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.54 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.54 |
| ▸ | KCNQ1 | P51787 | 2/20 | 0.54 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 2/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | GPR183 | P32249 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30308280 | 1.00 | KIF11 (0.56) | KIF11KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL759728 | 0.85 | KCNQ3 (0.54) | KIF11KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL31542017 | 0.84 | NOTUM (0.42) | KIF11KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL2680326 | 0.84 | NOTUM (0.42) | KIF11KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL850429 | 0.82 | KIF11 (0.57) | KIF11KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL29620952 | 0.82 | KIF11 (0.57) | KIF11KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL8151708 | 0.81 | CES2 (0.47) | KIF11KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL10532934 | 0.81 | KMO (0.43) | KIF11KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL20560270 | 0.81 | KIF11 (0.50) | KIF11KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL1031838 | 0.81 | KIF11 (0.56) | KIF11KCNQ3KCNQ2KCNE1KCNQ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295115-A1 | SUBSTITUTED ISOQUINOLINYLMETHYL AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2023-09-21 | — | — | US | disclosed |
| CN-116535358-A | Benzamide derivative with sulfur-containing cyano pyrazole structure, preparation method and application thereof | 西北农林科技大学 | 2023-08-04 | — | — | CN | disclosed |
| EP-4161916-A1 | SUBSTITUTED ISOQUINOLINYLMETHYL AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | Arbutus Biopharma Corporation (CA) | 2023-04-12 | — | — | EP | disclosed |
| WO-2023288253-A1 | SMALL MOLECULES INHIBITORS OF CYCLIC GMP-AMP SYNTHASE (CGAS) | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-01-19 | — | — | WO | disclosed |
| US-11390610-B2 | Piperazine derivatives as MAGL inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2022-07-19 | — | — | US | disclosed |
| WO-2021250461-A1 | SUBSTITUTED ISOQUINOLINYLMETHYL AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-12-16 | — | — | WO | disclosed |
| EP-3694840-B1 | PIPERAZINE DERIVATIVES AS MAGL INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-08-04 | — | — | EP | disclosed |
| CN-108698982-B | Fluorine atom-containing compound and use thereof | 日产化学工业株式会社 | 2021-07-16 | — | — | CN | disclosed |
| US-20200299277-A1 | PIPERAZINE DERIVATIVES AS MAGL INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2020-09-24 | — | — | US | disclosed |
| US-10781180-B2 | 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2020-09-22 | — | — | US | disclosed |
| WO-2006114402-A1 | SUBSTITUTED OCTAHYDROISOINDOLES AS ANTAGONISTS OF MELANIN CONCENTRATING HORMONE RECEPTOR 1 (MCH1R) | BIOVITRUM AB (PUBL) (SE) | 2006-11-02 | — | — | WO | disclosed |
| US-20060173018-A1 | Quinazolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2006-08-03 | — | — | US | disclosed |
| WO-2006028904-A9 | QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2006-06-22 | — | — | WO | disclosed |
| WO-2006055734-A2 | 3-PHENYL-PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2006-05-26 | — | — | WO | disclosed |
| WO-2006028904-A1 | QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-03-16 | — | — | WO | disclosed |
| EP-1599202-A1 | TETRACYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | Pharmacia Italia S.p.A. (IT) | 2005-11-30 | — | — | EP | disclosed |
| US-20050143398-A1 | Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-06-30 | — | — | US | disclosed |
| WO-2005042537-A1 | PHENYL-ANILINE SUBSTITUTED BICYCLIC COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-05-12 | — | — | WO | disclosed |
| CN-1538960-A | Amino-2, 3-naphthyridinone derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | — | 2004-10-20 | — | — | CN | disclosed |
| WO-2004071507-A1 | TETRACYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | PHARMACIA ITALIA S.P.A. (IT) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295115-A1 | SUBSTITUTED ISOQUINOLINYLMETHYL AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | HCCS, HAVCR2, HDGF | KIF11 4307/4885KCNQ3 3494/4885KCNQ2 3321/4885 |
| US-11390610-B2 | Piperazine derivatives as MAGL inhibitors | MAGI3, PYM1, MAG | KIF11 185/4885KCNQ3 968/4885KCNQ2 448/4885 |
| US-20060173018-A1 | Quinazolines useful as modulators of ion channels | KCNQ1, KCNQ2, KCNN3 | KIF11 2691/4885KCNQ3 10/4885KCNQ2 2/4885 |
| US-20200299277-A1 | PIPERAZINE DERIVATIVES AS MAGL INHIBITORS | MAGI3, PYM1, MAG | KIF11 185/4885KCNQ3 968/4885KCNQ2 448/4885 |
| US-20050143398-A1 | Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors | MAP4K2, MAP3K19, MAP3K1 | KIF11 1397/4885KCNQ3 982/4885KCNQ2 870/4885 |
| US-10781180-B2 | 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | HTR5A, HTR3A, HTR2A | KIF11 4401/4885KCNQ3 611/4885KCNQ2 684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.